(Reuters) - WASHINGTON, May 23 - Contrast agents used to make magnetic resonance imaging, or MRI, scans easier to see should carry new, strong warnings, the U.S. Food and Drug Administration said on Wednesday.
The warning -- a "black box" -- would alert patients with certain kidney and liver conditions that they are at risk for a potentially fatal skin disease called nephrogenic systemic fibrosis, the agency said in a statement.
Read more at Reuters.com Government Filings News
The warning -- a "black box" -- would alert patients with certain kidney and liver conditions that they are at risk for a potentially fatal skin disease called nephrogenic systemic fibrosis, the agency said in a statement.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment